Pharmacodynamic monitoring of immunosuppressive effects indicates reduced cyclosporine activity during telaprevir therapy

Liver Transplantation

Volumn 20, Issue 9, 2014, Pages 1106-1117

  Roos, Katja ^a   Gotthardt, Daniel ^a   Giese, Thomas ^a   Schnitzler, Paul ^a   Stremmel, Wolfgang ^a   Czock, David ^a   Eisenbach, Christoph ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; MESSENGER RNA; TELAPREVIR; TRANSCRIPTION FACTOR NFAT; ANTIVIRUS AGENT; BIOLOGICAL MARKER; CYCLOSPORIN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFNG PROTEIN, HUMAN; IL2 PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; OLIGOPEPTIDE; VIRUS RNA;

ACUTE GRAFT REJECTION; ADULT; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; CHOLESTATIC HEPATITIS; CLINICAL ARTICLE; COHORT ANALYSIS; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETRANSPLANTATION; RETROSPECTIVE STUDY; TREATMENT DURATION; VIRUS REACTIVATION; ADVERSE EFFECTS; BLOOD; COMPLICATION; DOSE RESPONSE; DRUG EFFECTS; DRUG INTERACTION; END STAGE LIVER DISEASE; GENE EXPRESSION REGULATION; GENETICS; HEPACIVIRUS; HEPATITIS C; LIVER TRANSPLANTATION; MIDDLE AGED; PREDICTIVE VALUE; PROCEDURES; RECURRENT DISEASE; TIME; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG INTERACTIONS; DRUG MONITORING; END STAGE LIVER DISEASE; FEMALE; GENE EXPRESSION REGULATION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; INTERLEUKIN-2; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; OLIGOPEPTIDES; PREDICTIVE VALUE OF TESTS; RECURRENCE; RETROSPECTIVE STUDIES; RNA, MESSENGER; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84906934768     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23925     Document Type: Article

References (28)

1. Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35: 680-687.
2. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al.; for HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217.
3. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al.; for SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
4. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al.; for REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428.
5. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al.; for ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
6. Brown KA, Fontana RJ, Russo MW, Levitsky J, Yoshida EM, Vargas HE, et al. Twice-daily telaprevir in combination with peginterferon alfa-2a/ribavirin in genotype 1 HCV liver transplant recipients: interim week 16 safety and efficacy results of the prospective, multicenter REFRESH study [abstract]. Hepatology 2013; 58 (suppl 1): 209A.
7. Werner CR, Egetemeyr DP, Nadalin S, Königsrainer A, Malek NP, Lauer UM, Berg CP,. Treatment of recurrent genotype 1 hepatitis C post-liver transplantation: single center experience with telaprevir-based triple therapy. Z Gastroenterol 2014; 52: 27-34.
8. Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol 2014; 60: 78-86.
9. Stravitz RT, Levitsky J, Dodge JL, Saxena V, Burton JR, Verna EC, et al. Higher sustained virologic response (SVR-12) achievable in liver transplant (LT) recipients with hepatitis C (HCV) treated with protease inhibitor (PI) triple therapy (TT) [abstract]. Hepatology 2013; 58 (suppl 1): 429A.
10. Crespo G, Mariño Z, Navasa M, Forns X,. Viral hepatitis in liver transplantation. Gastroenterology 2012; 142: 1373.e1.
11. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T,. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993; 268: 6077-6080.
12. Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X,. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 20-27.
13. Coilly A, Roche B, Samuel D,. Current management and perspectives for HCV recurrence after liver transplantation. Liver Int 2013; 33 (suppl 1): 56-62.
14. Fontana RJ, Qiu R, Russo MW, Yoshida EM, Brown KA, Levitsky J, et al. Twice-daily telaprevir in combination with peginterferon alfa-2a/ribavirin in genotype 1 HCV liver transplant recipients: interim week 16 calcineurin inhibitor, telaprevir, and ribavirin pharmacokinetics from the prospective multicenter REFRESH study [abstract]. Hepatology 2013; 46 (suppl 1): 1043A.
15. Vogel M, Voigt E, Michaelis HC, Sudhop T, Wolff M, Türler A, et al. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. Liver Transpl 2004; 10: 939-944.
16. Citterio F,. Evolution of the therapeutic drug monitoring of cyclosporine. Transplant Proc 2004; 36 (suppl): 420S-425S.
17. Treckmann J, Paul A, Ozcelik A, Saner F, Malagõ M, Nadalin S, et al. Efficacy of C0 and C2 monitoring in adult liver transplant recipients treated with neoral, mycophenolate mofetil, and steroids. Transplant Proc 2007; 39: 3234-3236.
18. Ogawa N, Kanda Y, Matsubara M, Asano Y, Nakagawa M, Sakata-Yanagimoto M, et al. Increased incidence of acute graft-versus-host disease with the continuous infusion of cyclosporine A compared to twice-daily infusion. Bone Marrow Transplant 2004; 33: 549-552.
19. Oshima K, Kanda Y, Nakasone H, Arai S, Nishimoto N, Sato H, et al. Decreased incidence of acute graft-versus-host disease by continuous infusion of cyclosporine with a higher target blood level. Am J Hematol 2008; 83: 226-232.
20. Giese T, Zeier M, Schemmer P, Uhl W, Schoels M, Dengler T, et al. Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A. Transplantation 2004; 77: 339-344.
21. Sommerer C, Zeier M, Czock D, Schnitzler P, Meuer S, Giese T,. Pharmacodynamic disparities in tacrolimus-treated patients developing cytomegalus virus viremia. Ther Drug Monit 2011; 33: 373-379.
22. Zahn A, Schott N, Hinz U, Stremmel W, Schmidt J, Ganten T, et al. Immunomonitoring of nuclear factor of activated T cells-regulated gene expression: the first clinical trial in liver allograft recipients. Liver Transpl 2011; 17: 466-473.
23. Giese T, Sommerer C, Zeier M, Meuer S,. Monitoring immunosuppression with measures of NFAT decreases cancer incidence. Clin Immunol 2009; 132: 305-311.
24. Buti M, Agarwal K, Horsmans Y, Sievert W, Janczewska E, Zeuzem S, et al. Efficacy of telaprevir dosed twice daily versus every 8 hours by IL28B genotype: results from the phase III OPTIMIZE study [abstract]. J Hepatol 2013; 58 (suppl 1): 326.
25. Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Königsrainer A, Malek NP, Berg CP,. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Liver Transpl 2012; 18: 1464-1470.
26. Bauer LA, Gibaldi M,. Computation of model-independent pharmacokinetic parameters during multiple dosing. J Pharm Sci 1983; 72: 978-979.
27. Sommerer C, Meuer S, Zeier M, Giese T,. Calcineurin inhibitors and NFAT-regulated gene expression. Clin Chim Acta 2012; 413: 1379-1386.
28. Herden U, Kromminga A, Hagel C, Hartleb J, Nashan B, Sterneck M, Fischer L,. Monitoring of nuclear factor of activated T-cell-regulated gene expression in de novo and long-term liver transplant recipients treated with cyclosporine A. Ther Drug Monit 2011; 33: 185-191.